Harnessing the power of antisense technology for combination chemotherapy.
Narayanan
R
R
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D003520:Cyclophosphamide / Q000494:pharmacology*; D004273:DNA, Neoplasm / Q000187:drug effects*; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000235:genetics; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D013677:Medical Laboratory Science; D051379:Mice; D016513:Mice, SCID; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D010677:Philadelphia Chromosome
D018906:Antineoplastic Agents, Alkylating; D004273:DNA, Neoplasm; D016376:Oligonucleotides, Antisense; D003520:Cyclophosphamide; D016044:Fusion Proteins, bcr-abl